The Joint Committee on Vaccination and Immunisation (JCVI) has published its advice on which vaccines should be used in this year’s autumn booster programme.
Article continues below
>
All of the available boosters provide good protection against severe illness from coronavirus (COVID-19).
The vaccines advised for use in the autumn booster programme are:
For adults aged 18 years and above:
• Moderna mRNA (Spikevax) bivalent Omicron BA.1/Original ‘wild-type’ vaccine
• Moderna mRNA (Spikevax) Original ‘wild-type’ vaccine
• Pfizer-BioNTech mRNA (Comirnaty) Original ‘wild-type’ vaccine
• in exceptional circumstances, the Novavax Matrix-M adjuvanted wild-type vaccine (Nuvaxovid) may be used when no alternative clinically suitable UK-approved COVID-19 vaccine is available
For people aged 12 to 17 years:
• Pfizer-BioNTech mRNA (Comirnaty) Original ‘wild-type’ vaccine
For people aged 5 to 11 years:
• Pfizer-BioNTech mRNA (Comirnaty) Original ‘wild-type’ vaccine paediatric formulation
‘Bivalent’ vaccines have been developed by global manufacturers since the emergence and dominance of the Omicron variant. These vaccines contain two different antigens (substances that induce an immune response) based on two different COVID-19 strains, or variants.
The original mRNA vaccines contain one antigen (monovalent), based on the original ‘wild-type’ strain.
Studies indicate the Moderna bivalent vaccine produces a marginally higher immune response against some variants than the Moderna mRNA Original ‘wild-type’ vaccine. The clinical relevance of these small differences is uncertain.
The committee will consider further bivalent vaccines for use in the programme as they are approved by the MHRA.
In its latest advice the JCVI has stated that, where feasible, it would be preferable for a single type of booster vaccine to be offered throughout the duration of the autumn programme for simplicity of deployment.
NHS England will confirm details on how and when eligible people can access the autumn booster vaccine in due course. ■